businesspress24.com - Equity Research on Forest Laboratories Inc. and Endo Pharmaceuticals Holdings Inc. - Drug Manufactur
 

Equity Research on Forest Laboratories Inc. and Endo Pharmaceuticals Holdings Inc. - Drug Manufacturers - Other Look to New Drugs to Combat Expirations

ID: 1027985

(firmenpresse) - JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 08/05/11 -- offers investors comprehensive research on the Drug Manufacturers - Other industry and has completed analytical research on (NYSE: FRX) and (NASDAQ: ENDP). Register with us today at to have free access to these researches.

The Drug Manufacturers - Other sector, like the rest of the pharmaceutical world, has a major cause for concern with the coming patent expirations during the next few years. As many big-revenue medications come off patent protection and become available for generic drug makers to copy and sell them, companies will have to find new ways to make up for lost revenue. Register now at to have free access to our reports on the Drug Manufacturers - Other industry.

is an online platform where investors doing their due-diligence on the Drug Manufacturers - Other industry can have easy and free access to our analyst research and opinions on Forest Laboratories Inc. and Endo Pharmaceuticals Holdings Inc.; investors and shareholders of these companies can simply register for a complimentary membership at .

Forest Laboratories Inc., for example, is optimistic about the expansion of sales for new drugs to help offset the loss of Lexapro's patent which expires in March 2012. The company which is currently embroiled in a conflict with Carl Icahn over positions on its board has gone as far as making new acquisitions to help bolster its drug portfolio. research report is accessible for free by registering today at .

This trend towards acquiring new drugs is common throughout the sector. With a new drug from BioSante Pharmaceuticals out to help improve low libido for women, many companies in the pharmaceutical world are interested in working a deal with the company. Endo Pharmaceuticals Holdings Inc. is thought to be one of the companies interested in the potentially $4 billion per year market. research report is available for free by signing up now at .

Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.





StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.






Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Research on First Niagara Financial Group Inc. and Flagstar Bancorp Inc. - Savings and Loans Woes Continue
Equity Research on Norfolk Southern Corporation and Kansas City Southern - Railroads Barreling Down the Tracks
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 05.08.2011 - 06:35 Uhr
Sprache: Deutsch
News-ID 1027985
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

JOHANNESBURG, SOUTH AFRICA


Phone:

Kategorie:

Commercial & Investment Banking


Anmerkungen:


Diese Pressemitteilung wurde bisher 116 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Equity Research on Forest Laboratories Inc. and Endo Pharmaceuticals Holdings Inc. - Drug Manufacturers - Other Look to New Drugs to Combat Expirations
"
steht unter der journalistisch-redaktionellen Verantwortung von

StockCall (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von StockCall



 

Who is online

All members: 10 567
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 83


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.